NCT00637065 - Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

August 31, 2010

Conditions

Pulmonary HypertensionInterstitial Lung DiseaseIdiopathic Pulmonary FibrosisNonspecific Interstitial Pneumonia

Interventions

DRUG

Bosentan

Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.

DRUG

Placebo

Placebo tables - identical to active drug but without the active ingredient -

Trial Locations (3)

St George's Hospital, London

Royal Brompton Hospital, London

Hammersmith Hospital, London